Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.ZEBOV + MVA-BN-Filo
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Ad26.ZEBOV + MVA-BN-Filo is a two-dose, heterologous Ebola vaccine regimen indicated for the prevention of disease caused by Zaire ebolavirus (Ebola virus) in individuals aged 1 year and older. The first dose, Ad26.ZEBOV (marketed as Zabdeno), is a monovalent, replication-incompetent adenovirus serotype 26 vector-based vaccine encoding the full-length glycoprotein of the Zaire ebolavirus Mayinga variant. The second dose, administered approximately eight weeks later, is MVA-BN-Filo (marketed as Mvabea), a recombinant non-replicating modified vaccinia Ankara vector-based multivalent filovirus vaccine encoding glycoproteins from Zaire ebolavirus (Mayinga variant), Sudan virus (Gulu variant), Marburg virus (Musoke variant), and nucleoprotein from Taï Forest virus. Both components are genetically modified so they cannot replicate in human cells but express viral proteins to stimulate an immune response. This regimen was authorized by the EMA in July 2020 and prequalified by WHO for use in outbreak settings and among at-risk populations including children and pregnant women[2][3][5][6][7].
- Brand names
- MvabeaZabdenoZabdeno + MvabeaZabdeno/Mvabea
- Other names
- Ad26.ZEBOV, MVA-BN-Filo vaccine regimenZEBOV/MVA-BN-Filo combination
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoproteinNP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on Ad26.ZEBOV + MVA-BN-Filo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.ZEBOV + MVA-BN-Filo.